HRMY (Harmony Biosciences Holdings) Moat Score: 4/10 (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HRMY Harmony Biosciences Holdings Inc HRMY
94 GF Score
Price $38.75
GF Value $46.93
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Harmony Biosciences Holdings Moat Score?

Harmony Biosciences Holdings HRMY +0.03% 94 Moat Score is 4 as of Aug. 07, 2026. GuruFocus rates HRMY with a GF Score™ of 94/100 and a GF Value™ of $46.93 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,393 Biotechnology companies, Harmony Biosciences Holdings ranks better than 88.8% on this metric.

Harmony Biosciences Holdings has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Harmony Biosciences Holdings has Narrow Moat: Harmony Biosciences has a discernible but modest moat, primarily due to its valuable patents in the pharmaceutical sector. However, it faces significant competition and regulatory challenges, limiting its overall competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Harmony Biosciences Holdings might have Narrow Moat - Discernible but modest moat.

Harmony Biosciences Holdings  (NAS:HRMY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Harmony Biosciences Holdings Moat Score Related Terms

HRMY vs SION, URGN, PVLA: Moat Score Comparison

For the Biotechnology subindustry, Harmony Biosciences Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harmony Biosciences Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Moat Score falls into.


HRMY
94GF Score
Harmony Biosciences Holdings Inc HRMY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Harmony Biosciences Holdings (HRMY) has a Moat Score of 4 as of Aug. 07, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Harmony Biosciences Holdings ranks #156 out of 1393 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Harmony Biosciences Holdings' Moat Score too high?
Harmony Biosciences Holdings' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Harmony Biosciences Holdings' value of 4 is 100% above this industry median. Based on the distribution chart, Harmony Biosciences Holdings ranks #156 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Harmony Biosciences Holdings has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Moat Score compare to SION and URGN?
According to the Biotechnology industry distribution chart, Harmony Biosciences Holdings ranks #156 out of 1393 companies for Moat Score. This places Harmony Biosciences Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Harmony Biosciences Holdings' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harmony Biosciences Holdings's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harmony Biosciences Holdings's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.93, compared to a current price of $38.75 — trading 17.4% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Harmony Biosciences Holdings' overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Moat Score is 4 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?

Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued. The current stock price of $38.75 is trading 17.4% below its estimated GF Value™ of $46.93. GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.

Key valuation signals for HRMY:

  • Moat Score: 4
  • GF Value™: $46.93 vs. price of $38.75 (17.4% below fair value)
  • GF Score™: 94/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#156 of 1393)

No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harmony Biosciences Holdings Business Description

Address 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score

Get the complete analysis for HRMY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.75
Price
$46.93
GF Value